Elinogrel

Antiplatelet therapy remains a cornerstone in the management of patients with coronary artery disease. Advances in platelet inhibition have led to the development of dual antiplatelet therapy that involves treatment with both aspirin and a P2Y12 receptor inhibitor. This dual antiplatelet therapy provides more potent platelet inhibition leading to a reduction in recurrent ischemic events, albeit at the cost of increased bleeding complications. Several P2Y12 receptor inhibitors have been developed, but side effects and other limitations have stimulated the search for novel antiplatelet agents. Elinogrel, a novel, small-molecule, direct-acting, competitive, reversible, intravenous (IV) and oral quinazolinedione P2Y12 receptor inhibitor, is promising given its direct-acting and rapid onset and offset of action, potent antiplatelet activity, oral and IV formulations, and suggested tolerability and efficacy in phase II studies; however, definitive conclusions cannot be made until phase III studies are conducted.

Duke Scholars

Author Sunil Vadlakonda Rao Medicine, Cardiology